Schütt, Katharina
Funding for this research was provided by:
RWTH Aachen University
Article History
Accepted: 19 October 2023
First Online: 4 December 2023
Declarations
:
: Dr. Schuett has received personal fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, MSD, Novo Nordisk, Novartis, and OmniaMed and served as a consultant for Amgen, AstraZeneca, Bayer, and Boehringer Ingelheim.
: This article does not contain any studies with human or animal subjects performed by any of the authors.